Mystery disease spreading in Congo, death toll at 31: WHO says
Thirty-one people, mostly children, have died due to an undiagnosed disease in the Democratic Republic of Congo, the WHO stated
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Thirty-one people, mostly children, have died due to an undiagnosed disease in the Democratic Republic of Congo, the WHO stated
The US regulator has granted a breakthrough therapy designation to British-Swedish AstraZeneca and Japan’s Daiichi Sankyo experimental drug for treating a certain type.
The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.
Amgen Inc., a US biotechnology company, will set up a second drug manufacturing facility in North Carolina for $1 billion, according to a.
Abnormal prenatal blood results are indicative of hidden cancers in pregnant women, researchers at the US nation’s medical research agency, the National Institutes.
HQ Team December 4, 2024: The CEO of United Health’s insurance arm, UnitedHealthcare, Brian Thompson, was shot dead Wednesday morning outside the Hilton.
Bharti Jayshankar December 3, 2024: A study conducted by researchers at Johns Hopkins University revealed concerning links between levothyroxine—a commonly prescribed medication for.
Bharti Jayshankar November 30, 2024: A study done by the University of Texas MD Anderson Cancer Center revealed that some breast cells in healthy.
Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.
Cassava Sciences Inc., a US-based biotechnology firm, announced its controversial experimental oral molecule to treat Alzheimer’s Disease has failed in last-stage trials.